2022 journal article
Determination of the efficacy rate and time‐to‐efficacy of subcutaneous immunotherapy in dogs with atopic dermatitis
Veterinary Dermatology, 33(2), 155.
MeSH headings : Allergens; Animals; Dermatitis, Atopic / drug therapy; Dermatitis, Atopic / veterinary; Desensitization, Immunologic / methods; Desensitization, Immunologic / veterinary; Dog Diseases / drug therapy; Dogs; Immunotherapy / methods; Immunotherapy / veterinary; Injections, Subcutaneous / veterinary; Pruritus / veterinary
TL;DR:
Novel SCIT regimens appear to have a faster - and possibly higher - efficacy than the currently available aqueous or alum-precipitated formulations.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science)
Source: ORCID
Added: December 10, 2021
BackgroundAllergen‐specific immunotherapy (ASIT) is reported to have a success rate of 50–70% when given for up to 12 months to dogs with atopic dermatitis (AD). How soon ASIT is clinically effective is unclear.